Home » J&J’s Codman Neuro Recall Upgraded to High Risk Class I
J&J’s Codman Neuro Recall Upgraded to High Risk Class I
Codman Neuro, a division of Johnson & Johnson subsidiary DePuy Synthes, said the FDA labeled its Trufill n-BCA liquid embolic system recall as Class I, the federal watchdog agency’s highest-risk classification.
MassDevice
MassDevice
Upcoming Events
-
07May
-
14May
-
30May